CONTEXT: In patients with acromegaly, cardiovascular complications are the main cause of death; sudden death has been associated with ventricular tachyarrhythmias. In other patients with life-threatening malignant ventricular tachyarrhythmias, surgical placement of an implantable cardioverter-defibrillator (ICD) has proved highly effective in reducing sudden death rates. CASE REPORT: The present article reports the case of a 50-year-old male acromegalic patient who presented symptoms of syncope induced by ventricular tachycardia. An ICD was surgically implanted and a pituitary adenoma, which was responsible for the acromegaly, was completely removed in the same procedure. The surgery was successful and the ventricular arrhythmias were effectively terminated. During six months of follow-up, no documented arrhythmic episodes occurred. CONCLUSION: In patients with acromegaly, malignant ventricular tachyarrhythmia might be effectively controlled by implantation of an ICD and surgical removal of the pituitary adenoma.
INTRODUCTION
Acromegaly is characterized by hypersecretion of growth hormone, which in more than 95% of patients is caused by a secreting pituitary tumor. 1 The high prevalence of arrhythmias and sudden cardiac death in these patients may be related to myocardial interstitial fibrosis. 2 Several clinical studies have reported the presence of premature ventricular contractions, 3 third-degree atrioventricular block 4, 5 and dilated cardiomyopathy 6 in patients with acromegaly. However, in a review of the literature regarding case reports on malignant ventricular tachyarrhythmia concomitant with hemodynamic instability and acromegaly, only one case was found. In 2010, Yokota et al. reported
that a 51-year-old man with a diagnosis of cardiac dysfunction with acromegaly was successfully treated by means of transsphenoidal surgery and normalization of growth hormone and insulin-like growth factor-1 (IGF-1), even in the presence of severe fibrosis in the myocardium. 7 In the present report, we describe a case of an acromegalic patient with recurrent ventricular tachyarrhythmia who underwent placement of an implantable cardioverter-defibrillator (ICD) and pituitary adenoma surgery. By searching in Medline (via PubMed),
Embase and Lilacs, with the search strategies shown in Table 1 , only one case report 7 was found, similar to ours.
CASE REPORT
A 50-year-old Han Chinese man was admitted to our hospital after several episodes of syncope during the previous week, with electrocardiographic evidence of monomorphic ventricular tachycardia.
On physical examination, increased head circumference, pronounced lower jaw protrusion with macroglossia and swelling of the soft tissues in the hands and feet were evident (Figure 1 ). (Figure 2) . The size and shape of his skull were increased. Scattered spots and flaky hyperintensity in T1 and T2, apparently normal heart. 13 Therefore, when occurrences of clinical arrhythmias and heart failure are not easily explained by cardiogenic causes, it seems reasonable to consider the possibility of acromegaly-associated cardiovascular complications.
Hidden symptoms and slow clinical progression make acromegaly difficult to diagnose, particularly in the early stages.
For this patient, ventricular tachyarrhythmia was definitively identified on admission, but its etiology was unclear. The possibility of acromegaly makes it extremely important to identify the specific heart disease responsible for arrhythmia when it occurs.
In this case, echocardiographic examination did not meet all the diagnostic criteria for dilated cardiomyopathy, although dilated cardiomyopathy may cause arrhythmia.
After careful physical examination, the typical signs of acromegaly in this case were identified. Moreover, cerebral MRI revealed the presence of an intracranial pituitary adenoma, and blood tests indicated that the serum level of growth hormone was elevated.
Presence of a pituitary adenoma is responsible for excessive levels of growth hormone, which leads to acromegalic cardiomyopathy. Cardiovascular complications might benefit from treatment directed towards the pituitary adenoma, and lowering the blood growth hormone levels might arrest further progression of myocardial hypertrophy. 14 Bromocriptine inhibits release and synthesis of prolactin by acting directly on the prolactin-secreting cells of the anterior pituitary. 15 In patients with acromegaly, bromocriptine treatment results in reduction of serum growth hormone levels, 16 which consequently blocks the unfavorable effect of growth hormone on the heart. Several studies have found that early heart attack could be effectively controlled after successful treatment of pituitary tumors, 17, 18 thus indicating that early-stage cardiovascular complications are reversible. For example, recent evidence has shown that normalization of growth hormone and IGF-1 can work even in the presence of severe fibrosis in the myocardium. 7 However, whether end-stage acromegalic cardiomyopathy is reversible is unknown. Unexpectedly, in the present case with end-stage acromegalic cardiomyopathy, after the resection of the pituitary adenoma, no arrhythmic episodes occurred during six months of follow-up.
CONCLUSION
Malignant ventricular tachyarrhythmia might be effectively controlled by implantation of an ICD, surgical removal of a pituitary adenoma and oral drug therapy.
